Cypherpunk Technologies (CYPH) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Fulcrum Therapeutics (FULC) over the past year, gaining 387.2% versus a loss of 60.3%. Over five years, FULC leads with a -85.9% price change compared with -90.3% for CYPH. Fulcrum Therapeutics is the larger company by market cap ($282.3 million vs $280.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYPH | FULC |
|---|---|---|
| Share price | $2.61 | $3.70 |
| Market cap | $280.73M | $282.30M |
| 1-day change | -14.62% | +0.82% |
| YTD return | +162.93% | -67.55% |
| 1-year return | +387.22% | -60.28% |
| 5-year return | -90.32% | -85.88% |
| P/E ratio (TTM) | 4.13 | — |
| EPS (TTM) | $0.63 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $15.74 |
| 52-week low | $0.393 | $2.83 |
| Distance from 52-week high | -37.83% | -76.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +88.10% | -0.81% |
| Average volume | 9.88M | 1.53M |
| Shares outstanding | 107.76M | 76.30M |
| Employees | 6 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed FULC by 447.5 percentage points over the past year.
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CYPH vs FULC FAQ
Which is bigger, Cypherpunk Technologies or Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $282.30M compared with $280.73M for Cypherpunk Technologies (CYPH).
Which stock has performed better over the past year, CYPH or FULC?
CYPH returned +387.22% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Cypherpunk Technologies and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.